Literature DB >> 21218523

Genetics: In colorectal cancer, not all KRAS mutations are created equal.

Rebecca Kirk.   

Abstract

Entities:  

Year:  2011        PMID： 21218523     DOI： 10.1038/nrclinonc.2010.204

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272
  1 in total
  3 in total

1.  Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.

Authors:  Elisabeth Pérez-Ruiz; A Rueda; T Pereda; J Alcaide; D Bautista; F Rivas-Ruiz; R Villatoro; D Pérez; M Redondo
Journal:  Tumour Biol       Date:  2012-07-13

2.  Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients.

Authors:  Krzysztof Roszkowski; Bogdan Zurawski; Wojciech Jozwicki; Pawel Basta; Marzena Anna Lewandowska
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

3.  Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.

Authors:  Peter J Belmont; Eva Budinska; Ping Jiang; Mark J Sinnamon; Erin Coffee; Jatin Roper; Tao Xie; Paul A Rejto; Sahra Derkits; Owen J Sansom; Mauro Delorenzi; Sabine Tejpar; Kenneth E Hung; Eric S Martin
Journal:  Dis Model Mech       Date:  2014-04-17       Impact factor: 5.758
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.